Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:ALKS

Alkermes (ALKS) Stock Price, News & Analysis

Alkermes logo
$43.63 -0.55 (-1.24%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$43.60 -0.03 (-0.06%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Alkermes Stock (NASDAQ:ALKS)

Advanced

Key Stats

Today's Range
$43.15
▼
$44.15
50-Day Range
$39.08
▼
$50.18
52-Week Range
$27.00
▼
$55.67
Volume
884,579 shs
Average Volume
2.27 million shs
Market Capitalization
$7.32 billion
P/E Ratio
114.82
Dividend Yield
N/A
Price Target
$54.47
Consensus Rating
Moderate Buy

Company Overview

Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders.

The company’s marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts. The company serves patients primarily through the United States pharmaceutical market and uses proprietary drug-delivery technologies, including long-acting injectable formulations, as part of its approach to developing treatments for complex and chronic conditions.

AI Generated. May Contain Errors.

Alkermes Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

ALKS MarketRank™: 
3.209255533195 of 5 stars

Alkermes scored higher than 64% of companies evaluated by MarketBeat, and ranked 281st out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on 1 strong buy rating, 12 buy ratings, 5 hold ratings, and 1 sell rating.

  • Upside Potential

    Alkermes has a consensus price target of $54.47, representing about 24.8% upside from its current price of $43.63.

  • Amount of Analyst Coverage

    Alkermes has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Alkermes' stock forecast and price target.
  • Earnings Growth

    Earnings for Alkermes are expected to grow in the coming year, from ($0.57) to $0.31 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alkermes is 114.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.39.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alkermes is 114.82, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.33.

  • Price to Book Value per Share Ratio

    Alkermes has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Alkermes' valuation and earnings.
  • Percentage of Shares Shorted

    11.13% of the float of Alkermes has been sold short.
  • Short Interest Ratio / Days to Cover

    Alkermes has a short interest ratio ("days to cover") of 6.28.
  • Change versus previous month

    Short interest in Alkermes has recently increased by 17.58%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Alkermes does not currently pay a dividend.

  • Dividend Growth

    Alkermes does not have a long track record of dividend growth.

  • News Sentiment

    Alkermes has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Alkermes this week, compared to 6 articles on an average week.
  • Search Interest

    Only 2 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,752,181.00 in company stock.

  • Percentage Held by Insiders

    4.59% of the stock of Alkermes is held by insiders.

  • Percentage Held by Institutions

    95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alkermes' insider trading history.
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALKS Stock News Headlines

Alkermes (ALKS) Expected to Post Earnings on Wednesday
Alkermes (ALKS) Receives a Buy from Needham
Why Gerardo Del Real says wait before buying uranium stocks
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.tc pixel
Truist Financial Begins Coverage on Alkermes (NASDAQ:ALKS)
Alkermes plc (NASDAQ:ALKS) Stock Has Consensus Price Target of $54.47
See More Headlines

ALKS Stock Analysis - Frequently Asked Questions

Alkermes' stock was trading at $27.98 at the beginning of the year. Since then, ALKS stock has increased by 55.9% and is now trading at $43.63.

Alkermes plc (NASDAQ:ALKS) announced its earnings results on Thursday, February, 26th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.43 by $0.14. The firm's revenue was down 10.6% on a year-over-year basis.
Read the conference call transcript
.

Alkermes subsidiaries include Rodin Therapeutics.

Alkermes' top institutional shareholders include Robeco Institutional Asset Management B.V. (0.03%), Yousif Capital Management LLC (0.03%), Nicollet Investment Management Inc. (0.03%) and State of Alaska Department of Revenue (0.02%). Insiders that own company stock include David Joseph Gaffin, Shane Cooke, Christian Todd Nichols, Craig C Hopkinson, Christopher I Wright, Cato T Laurencin and Nancy Lynn Md Snyderman.
View institutional ownership trends
.

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Bristol Myers Squibb (BMY), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), Intel (INTC), Gilead Sciences (GILD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
2/26/2026
Today
10/25/2026
Next Earnings (Estimated)
11/03/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALKS
CIK
1520262
Employees
2,050
Year Founded
1987

Price Target and Rating

High Price Target
$65.00
Low Price Target
$36.00
Potential Upside/Downside
+24.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.68
Research Coverage
19 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.38
Trailing P/E Ratio
114.82
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$241.66 million
Net Margins
3.96%
Pretax Margin
5.84%
Return on Equity
4.15%
Return on Assets
2.19%

Debt

Debt-to-Equity Ratio
0.82
Current Ratio
2.30
Quick Ratio
1.85

Sales & Book Value

Annual Sales
$1.67 billion
Price / Sales
4.39
Cash Flow
$1.67 per share
Price / Cash Flow
26.06
Book Value
$11.02 per share
Price / Book
3.96

Miscellaneous

Outstanding Shares
167,763,000
Free Float
160,063,000
Market Cap
$7.32 billion
Optionable
Optionable
Beta
0.32

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:ALKS) was last updated on 10/23/2026 by MarketBeat.com Staff.
From Our Partners